Abstract: Objective The objective of this study was to investigate the relationship between the methylation and clinical features of deubiquitinating enzyme USP1 in peripheral blood and the prognosis risk of colorectal cancer.Methods A total of 286 patients with colorectal cancer were enrolled in the cohort study.The level of DNA methylation status of USP1 was detected using high resolution melting curve analysis(HRM).The Cox regression model was used to assess the association between USP1 methylation and clinical features and prognosis risk of colorectal cancer.Results In male colorectal cancer cases,USP1 methylation could incerease the risk of colorectal cancer with poor pregnosis(HR=2.091,95% CI:1.195~3.661,P=0.010).Among the clinicopathological features,UICC tumor stage 4(HR=2.464,95% CI:1.205~5.039,P=0.014),tumor size over 50 mm(HR=1.610,95% CI:1.016~2.550,P=0.043)and histological non-adenotype(HR=5.117,95% CI:1.142~22.930,P=0.033)were contributing factors to the increased risk of colorectal cancer with poor pregnosis.Conclusion UICC tumor stage 4,tumor size over 50 mm and histological non-adenotype will increase the risk of colorectal cancer with poor pregnosis.The methylation of promoter region of USP1 gene in peripheral blood is associated with an increased risk of poor pregnosis in male colorectal cancer.

Key words: Colorectal cancer(CRC), DNA methylation, USP1